• Advancing gastrointestinal health naturally

    Our Gastrointestinal ReProgramming (GaRP) product is a microbiome-targeted multi-component dietary supplement that has been designed to address the primary underlying factors associated with gastrointestinal disorders. More >>

  • Anatara CEO presents at Monsoon Twilight Briefing

    Anatara Lifesciences CEO, Mr Steven Lydeamore, recently presented to investors at the Monsoon Communications Twilight Briefing in Melbourne. More >>

  • Successful GaRP Proof of Concept Studies

    Anatara’s unique Gastrointestinal ReProgramming (GaRP) dietary supplement has been shown to significantly reduce inflammation and protect and maintain gut integrity in recent in vitro studies. More >>

  • Anatara Lifesciences brings new hope for sufferers of IBS

    Since 1997, April has been designated as Irritable Bowel Syndrome (IBS) Awareness Month to focus attention on important health messages about IBS. Anatara is developing a new dietary supplement for sufferers of IBS that will help manage their condition and associated symptoms. More >>

  • Unite for World IBD Day

    Anatara Lifesciences supports the global campaign to raise IBD awareness. More than 10 million people worldwide live with Crohn’s disease or Ulcerative colitis. Each year on World IBD Day (19th May), we ask you to join with us to build awareness of these debilitating digestive diseases. More >>

Company description

Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. The Company is focused on building a pipeline of human gastrointestinal health products.

Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Recent coverage



Investors Home